Protein Expression Systems Market

Protein Expression Systems Market Overview

Advances in genetic engineering and cloning techniques have allowed isolation and expression of heterologous and recombinant proteins for research, therapeutic and industrial uses. Large scale applications such as enzyme, antibody or vaccine production require high amounts of protein. This demands that the system producing protein must be easy to culture, allow rapid cell growth and provide good yield. Various expression systems based on the machinery of bacteria, yeast, insect or mammalian cells have been developed to cater to these demands.

Protein synthesis occurs differently in prokaryotic and eukaryotic systems; the need for post translational modifications adds a level of complexity in the latter case. Newer expression systems utilising yeast and insect cells as host are gaining momentum due to favourable culture conditions and final end products. Pichia and Sf9/Sf21 host cells have emerged as the most commonly used systems in these categories, respectively. Some plant based technologies express protein rapidly, unlike the traditional methods of production in transgenic plants. Several other expression systems based on protozoa and fungi have also demonstrated effective protein expression. In addition, cell free expression systems have also been developed and are gaining momentum in the market.

The highly lucrative biologics market presents a huge opportunity for such systems. Both large and small companies in this sector have developed proprietary recombinant protein expression techniques to carve out their own share of the multi-billion dollar market. The increasing demand for biologics has led to the involvement of various CMOs providing services in protein expression. However, there are sometechnical shortcomings in current platforms which need to be dealt with to maximize the available opportunity. The opportunity, overall, will continue to increase manifold with the approval of several new biologics and biosimilars in the coming few years.

Recent Developments in Proteins Expression System Market:

Several recent developments have taken place in the field of protein expression system. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In May 2023, 10x Genomics launched a new Visium CytAssist Gene and Protein Expression product with an aim to strengthen its Visium CytAssist spatial analysis capabilities.

Scope of the Report

The “Protein Expression Systems Market: Current Landscape and Future Opportunities” report provides an extensive study of the various expression systems commercially available for the purpose of expressing the desired proteins. Selecting an effective and reliable expression system is one of the pre-requisites for pharma companies before they start proof of concept studies for biological molecules. It is well known that a particular expression system is not suitable to express every kind of protein. As such, there are several different types of platforms available to meet the growing demand.

With an extensive pipeline of biologic drugs, protein expression systems are likely to continue to garner significant attention from the biopharmaceutical industry. The report covers various aspects such as key features of these systems, associated products, licensing and services portfolio. We have also covered specific details on CMOs manufacturing biopharmaceutical products highlighting their capabilities, geographical location, scale of operation, type of biologics being manufactured and expression systems being used.

In addition, the report highlights the future growth prospects with respect to manufacturing biological molecules. We have analyzed the overall biologics pipeline and provided specific details on some important classes such as antibody drug conjugates (ADCs) and bispecific antibodies. Further, we have highlighted the emerging opportunity presented by the ongoing development of biosimilars. For the purposes of the study, we interviewed important stakeholders to solicit their opinions around the upcoming opportunities and challenges which must be considered for a more inclusive growth. Examples of companies we interviewed include Research Corporation Technologies, iBio and Jena Bioscience.